Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: Examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer

Oncology Reports

Volumn 11, Issue 4, 2004, Pages 899-903

  Tsavaris, Nicolas ^a   Kosmas, C ^a   Zorzos, H ^a   Lazaris, A ^a   Vadiaka, M ^a   Dimitrakopoulos, A ^a   Siakantaris, M P ^a   Rokana, S ^a   Papalambros, E ^a   Pangalis, G A ^a   Davaris, P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CELL SURFACE RECEPTOR; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P; LEUKOCYTE COMMON ANTIGEN RELATED PHOSPHATASE; LEUKOCYTE COMMON ANTIGEN-RELATED PHOSPHATASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; PREDNISONE; PROTEIN TYROSINE PHOSPHATASE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; DRUG RESISTANCE; FEMALE; HUMAN; IMMUNOCHEMISTRY; METABOLISM; MIDDLE AGED; NONHODGKIN LYMPHOMA; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOCHEMISTRY; LYMPHOMA, NON-HODGKIN; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PREDNISONE; PROGNOSIS; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 16544386464     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.4.899     Document Type: Article

References (24)

1. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati Bellani F and Meadows AT: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334: 745-751, 1996. (Pubitemid 26089355)
2. Cutuli B, Dhermain F, Borel C, De-Larochefordiere A, Graic Y, De-Lafontan B, Dilhyudy JM, Mignotte H, Tessier E, Tortochaux J, N'Guyen T, Bey P, Le Mevel Le Pourhiet A, Velten M and Arriagada R: Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients. Eur J Cancer 33: 2315-2320, 1997. (Pubitemid 28129169)
3. Biadler JL and Reihm H: Cellular resistance to actinomycin D in Chinese hamster ovary cells in vitro: cross-resistance, radio-autographic and cytogenetic studies. Cancer Res 34: 1174-1178, 1970.
4. Nooter K and Stoter G: Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 192: 768-780, 1996. (Pubitemid 26302251)
5. Scheper RJ, Broxterman HJ, Scheffer GL, Meijer CJ and Pinedo HM: Drug trasport protein in clinical multidrug resistance. Clin Chim Acta 206: 25-32, 1992.
6. Plumb J and Kaye SB: The cell membrane and drug resistance. Cancer Top 6: 30-34, 1986.
7. Kim R: Expression of the multidrug resistance gene in human tumors. Hiroshima J Med Sci 39: 71-77, 1990.
8. Crathorne AR and Roberts JJ: Mechanism of the cytotoxic action of alkylating agents in mammalian cells and evidence for the removal of the alkylated groups from deoxyribonucleic acid. Nature 211: 150-153, 1966.
9. Shustik C, Dalton W and Gros P: P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 16: 1-78, 1995.
10. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurtz EU, Duncan AMV and Deeley RC: Overexpression of a transport gene in a multidrug resistant human lung cancer cell line. Science 258: 1650-1655, 1992.
11. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen THM, van Kalken CK, Slovak ML, De Vries EGE, van de Valk P, Meijeer CJLM and Pinedo HM: Overexpression of a Mr 110.000 vesicular protein in non-P glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479, 1993. (Pubitemid 23113213)
12. Schlaifer D, Laurent G, Chittal S, Tsuruo T, Soues S, Muller C, Charcosset JY, Alard C, Brousset P, Mazerrolles C, et al: Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumor and stromal cells of human cancers. Br J Cancer 62: 177-182, 1990. (Pubitemid 20242431)
13. Nooter K, Westerman AM, Flens MJ, Zaman GJ, Scheper RJ, van-Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, et al: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1: 1301-1310, 1995.
14. Iizquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P and Scheper RJ: Broad distribution of the multidrug resistance related vault lung resistance protein in normal human tissues and tumors. Am J Clin Pathol 148: 877-887, 1996. (Pubitemid 126660679)
15. Alexander D, Yamamoto T, Kato S and Kasai S: Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today 29: 401-406, 1999. (Pubitemid 29272563)
16. Johnstone A and Thorpe R: Immunohistochemistry in Practice. 2nd edition. Blackwell Scientific Publications, London, pp261-289, 1987.
17. Cobleigh M, Vogel C, Tripathy D, Robert RJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999. (Pubitemid 29415219)
18. Dixon WJ and Massey FJ Jr: Introduction to Statistical Analysis. 4th edition. McGraw-Hill, New York, 1983.
19. Hancock SL, Tucher MA and Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85: 25-31, 1993. (Pubitemid 23023219)
20. Bradshaw DM and Arcesi RJ: Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16: 3674-3690, 1998. (Pubitemid 28506783)
21. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol 17: 1061-1070, 1999. (Pubitemid 29109340)
22. Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L and Silingardi V: Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 44: 185-192, 1977.
23. Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemo-resistance in hematologic malignancies. Semin Hematol 34 (Suppl 5): 9-19, 1997.
24. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G and Johnston SR: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48: 107-116, 1998. (Pubitemid 28156355)